FANCM and breast cancer: Peterlongo et al. (2015) [14] performed a multinational study genotyping the rs144567652 variant in 8635 BRCA1/2-negative familial BC cases and 6625 controls from Italy, France, Spain, Germany, Australia, the United States, Sweden, and the Netherlands, confirming an association between truncating FANCM mutations and BC risk, with a carrier frequency of 0.21% in cases and 0.06% in controls, and an OR of 3.93 (95% CI = 1.28–12.11; p = 0.017).